Microbiome

An average person contains 30 trillion human cells, but even more microbes – about 39 trillion. In addition, there are possibly ten times that number of viral particles in the human virome. Understanding an individual’s microbiome is becoming increasingly important for diagnosing a broad range of diseases.

Patents that relate to the microbiome often need to be drafted differently from patents covering small molecule drugs or conventional diagnostics. For instance, some inventions lie in a way of affecting or detecting a heterogenous population of microbial cells. The cells could be defined in various ways, such as by their function or by their degree of genetic relatedness to a reference organism. Other inventions lie in a way of assessing the impact of the heterogenous population of microbes on drug metabolism, which might require functional definitions and/or specific assays to be written into the claims.

Applicants for microbiome-based patents need to be aware of legal obstacles in certain jurisdictions that would make certain claims very difficult to obtain. At Mewburn Ellis LLP, our world class training and broad experience makes us an excellent choice to be your creative, trusted advisors in this rapidly developing space.

To find out more, view our spotlight page here.

Open pages of EPO Opposition Trends in the Life Sciences Sector

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

Event - From Innovation to Impact: Resolving Pinch Points in Cell and Gene Therapies, 23 July

Event - From Innovation to Impact: Resolving Pinch Points in Cell and Gene Therapies, 23 July

by Adam Gregory

On Wednesday 23 July, we were delighted to host our panel discussion and networking event "From Innovation to Impact: Resolving Pinch Points in Cell and Gene Therapies", featuring an incredible ...

Leucid Bio: the next generation of CAR T-cell therapies

Leucid Bio: the next generation of CAR T-cell therapies

by Laura Carney

CAR T-cell therapies hold the promise of curing solid tumour cancers. Dr John Maher, Chief Scientific Officer of Leucid Bio, explains how his biotech is developing the technology. Forward: features ...

At the Cutting Edge of Bioinformatics with Camille Terfve

At the Cutting Edge of Bioinformatics with Camille Terfve

by Camille Terfve

Mewburn Ellis partner Camille explains how her love for maths, biotech and the law come together in her remarkable role. Forward: features are independent pieces written for Mewburn Ellis discussing ...

Longevity Deals and IP Strategy

Longevity Deals and IP Strategy

by Katherine Collins

The recent announcement that Roche-backed Chugai Pharmaceutical has partnered with Gero to tackle age-related disease is the latest in a series of collaborations signalling growing interest from ...

Most opposed companies at the EPO in 2024

Most opposed companies at the EPO in 2024

by Katherine Green

Opposition activity at the European Patent Office is often a strong indicator of a technology’s commercial relevance. We analysed the companies holding the highest numbers of European patents that ...

Mewburn Ellis is proud to have worked on 24 of the 100 top-selling pharmaceuticals of 2024

Mewburn Ellis is proud to have worked on 24 of the 100 top-selling pharmaceuticals of 2024

by Adam Gregory

Mewburn Ellis works with some of the world’s most important pharmaceuticals and biologics across a broad range of therapeutic areas.

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.